The longterm followup results of a phase 12 retinal gene therapy clinical trial for choroideremia support the safety and efficacy of the treatment httpsgo.nature.com2QLUGz8Âpic.twitter.comXVc7KvafMj

The long-term follow-up results of a phase 1/2 retinal gene therapy clinical trial for choroideremia support the safety and efficacy of the treatment: https://go.nature.com/2QLUGz8 pic.twitter.com/XVc7KvafMj

10:30 EDT 15 Oct 2018 | Nature Publishing

The long-term follow-up results of a phase 1/2 retinal gene therapy clinical trial for choroideremia support the safety and efficacy of the treatment: https://go.nature.com/2QLUGz8  pic.twitter.com/XVc7KvafMj

More From BioPortfolio on "The long-term follow-up results of a phase 1/2 retinal gene therapy clinical trial for choroideremia support the safety and efficacy of the treatment: https://go.nature.com/2QLUGz8 pic.twitter.com/XVc7KvafMj"